Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent Starts China Phase II Trial of FGFR1/2/3 Inhibitor for Cholangiocarcinoma

publication date: Mar 4, 2020

Suzhou Innovent Biologics has dosed the first patient in a pivotal China Phase II trial of pemigatinib (IBI375), a FGFR1/2/3 inhibitor. The trial is designed to evaluate the efficacy and safety of pemigatinib in patients with advanced cholangiocarcinoma. Innovent acquired greater China rights from Incyte for the candidate in late 2018 as part of a $390 million, three-drug deal. In November 2019, Incyte submitted an NDA in the US for pemigatinib under priority review rules. More details...

Stock Symbol: (HK: 01801) (NSDQ: INCY)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.